Skip to content
Medical Health Aged Care, Science

Ultrathin nanotech promises to help tackle antibiotic resistance

RMIT University 3 mins read

Researchers have invented a nano-thin superbug-slaying material that could one day be integrated into wound dressings and implants to prevent or heal bacterial infections.

The innovation – which has undergone advanced pre-clinical trials – is effective against a broad range of drug-resistant bacterial cells, including ‘golden staph’, which are commonly referred to as superbugs.

Antibiotic resistance is a major global health threat, causing about 700,000 deaths annually, a figure which could rise to 10 million deaths a year by 2050 without the development of new antibacterial therapies.

The new study led by RMIT University and the University of South Australia (UniSA) tested black phosphorus-based nanotechnology as an advanced infection treatment and wound healing therapeutic.

Results published in Advanced Therapeutics show it effectively treated infections, killing over 99% of bacteria, without damaging other cells in biological models.

The treatment achieved comparable results to an antibiotic in eliminating infection and accelerated healing, with wounds closing by 80% over seven days.

The superbug-killing nanotechnology developed by RMIT was rigorously tested in pre-clinical trials by wound-healing experts at UniSA. RMIT has sought patent protection for the black phosphorus flakes including its use in wound healing formulations, including gels.

RMIT co-lead researcher, Professor Sumeet Walia, said the study showed how their innovation provided rapid antimicrobial action, then self-decomposed after the threat of infection had been eliminated.

“The beauty of our innovation is that it is not simply a coating – it can actually be integrated into common materials that devices are made of, as well as plastic and gels, to make them antimicrobial,” said Walia from RMIT’s School of Engineering.

A previous study led by RMIT revealed that black phosphorus was effective at killing microbes when spread in nano-thin layers on surfaces used to make wound dressings and implants such as cotton and titanium, or integrated into plastics used in medical instruments.

How the invention works

Black phosphorus is the most stable form of phosphorus - a mineral that is naturally present in many foods - and, in an ultra-thin form, degrades easily with oxygen, making it ideal for killing microbes.

“As the nanomaterial breaks down, its surface reacts with the atmosphere to produce what are called reactive oxygen species. These species ultimately help by ripping bacterial cells apart,” Walia said.

The new study tested the effectiveness of nano-thin flakes of black phosphorus against five common bacteria strains, including E. coli and drug-resistant golden staph.

“Our antimicrobial nanotechnology rapidly destroyed more than 99% of bacterial cells – significantly more than common treatments used to treat infections today.”

The global war on superbugs

Co-lead researcher Dr Aaron Elbourne from RMIT said healthcare professionals around the world were in desperate need of new treatments to overcome the problem of antibiotic resistance.

“Superbugs – the pathogens that are resistant to antibiotics – are responsible for massive health burdens and as drug resistance grows, our ability to treat these infections becomes increasingly challenging,” Elbourne, a Senior Research Fellow in RMIT’s School of Science, said.

“If we can make our invention a commercial reality in the clinical setting, these superbugs globally wouldn’t know what hit them.”

Treatment efficacy in preclinical models of wound infection

Lead researcher from UniSA, Dr Zlatko Kopecki, and his team performed the pre-clinical trials to show how daily topical application of the black phosphorus nanoflakes significantly reduced infection.

“This is exciting as the treatment was comparable to the ciprofloxacin antibiotic in eradicating wound infection and resulted in accelerated healing, with wounds closing by 80% over seven days,” Dr Kopecki said.

Dr Kopecki, who is also a Channel 7 Children’s Research Foundation Fellow in Childhood Wound Infections, said antibiotic treatments are becoming scarce.

“We urgently need to develop new alternative non-antibiotic approaches to treat and manage wound infection,” he said.

“Black phosphorus seems to have hit the spot and we look forward to seeing the translation of this research towards clinical treatment of chronic wounds.”

The team wants to collaborate with potential industry partners to develop and prototype the technology.

Layered Black Phosphorus Nanoflakes Reduce Bacterial Burden and Enhance Healing of Murine Infected Wounds’ is published in Advanced Therapeutics (DOI: 10.1002/adtp.202300235).

Emmeline P. Virgo, Hanif Haidari, Z. L. Shaw, Louisa Z. Y. Huang, Tahlia L. Kennewell, Luke Smith, Taimur Ahmed, Saffron J. Bryant, Gordon S. Howarth, Sumeet Walia, Allison J. Cowin, Aaron Elbourne and Zlatko Kopecki are co-authors.

Multimedia: 

Here’s a link to high-res images and b-roll video footage: https://cloudstor.aarnet.edu.au/plus/s/wVcBGUY2zBg75p6


Contact details:

For media assistance, contact Will Wright on 0417 510 735 or at will.wright@rmit.edu.au

More from this category

  • Disability, Medical Health Aged Care
  • 20/12/2024
  • 17:36
Kuremara

Kuremara to Open a State-of-the-Art Activity Center in Milton, QLD, in January 2025

Kuremara, a trusted and leading NDIS-registered provider in Australia, is excited to announce the opening of its newest facility—a cutting-edge activity center in Milton,…

  • Contains:
  • Legal, Medical Health Aged Care
  • 20/12/2024
  • 17:29
JGA Saddler

BREAKING NEWS: Australian law firm takes on Johnson & Johnson for selling Australians ineffective medicine

Vision available: Lawyer and doctor VNR, editorial photos and radio grabs included can be found in this SharePoint File In-person lawyer interviews available by…

  • Contains:
  • Medical Health Aged Care
  • 20/12/2024
  • 12:01
NDARC/UNSW

ADHD drug shows promise for treating methamphetamine dependence, landmark Australian study shows

A prescription medication used to treat attention deficit hyperactivity disorder (ADHD) could be repurposed as the first pharmacotherapy for people with methamphetamine dependence, according to a study published in Addiction. Results from the landmark ‘LiMA’ trial show that thepsychostimulant lisdexamfetamine can drastically reduce the need to use methamphetamine among those who are dependent on the illicit drug. Lead author and addiction medicine specialist Professor Nadine Ezard, who is Director of the National Centre for Clinical Research on Emerging Drugs (NCCRED), said the results were promising. "There is currently no pharmacotherapy approved for treating methamphetamine dependence," Professor Ezard said. “While further…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.